Hepatology International

, Volume 5, Issue 2, pp 664–670 | Cite as

A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B

  • Su Rin Shin
  • Byung Chul Yoo
  • Moon Seok Choi
  • Dong Ho Lee
  • Soon Mi Song
  • Joon Hyoek Lee
  • Kwang Cheol Koh
  • Seung Woon Paik
Original Article

Abstract

Purpose

Clevudine and entecavir are currently available in Korea as antiviral drugs against chronic hepatitis B (CHB). We aimed to compare the efficacy of clevudine and entecavir therapy.

Methods

Treatment-naïve CHB patients who received 30 mg of clevudine or 0.5 mg of entecavir a day were analyzed. Mean reduction of hepatitis B virus (HBV) DNA levels, complete virological response (cVR, undetectable HBV DNA by real-time PCR), biochemical response (recovery to normal ALT level), and hepatitis B e antigen (HBeAg) seroconversion rate at the 48th week of treatment were assessed.

Results

A number of 59 patients in clevudine group and 61 patients in entecavir group were included. Mean HBV DNA reductions from baseline were similar in the clevudine and entecavir groups, −6.4 versus −6.8 log10 copies/mL in HBeAg-positive (p = 0.417) and −6.9 versus −7.0 log10 copies/mL in HBeAg-negative patients (p = 0.640). The proportion of patients who achieved cVR was not different between the two groups, 53 versus 55% in HBeAg-positive (p = 1.000) and 100 versus 95% in HBeAg-negative patients (p = 0.452). Biochemical response rates and HBeAg seroconversion rates were also similar in both the groups. Two (3.4%) patients in clevudine group showed virologic breakthrough with rtM204I mutation using direct sequencing analysis. Clinical myopathy occurred in two (3.4%) patients in clevudine group.

Conclusion

Mean reduction of viral loads was similar between clevudine and entecavir groups during 48 weeks. However, virologic breakthrough and significant myopathy were noted only in clevudine-treated patients. Therefore, more attention should be paid to patients receiving clevudine.

Keywords

Hepatitis B virus Clevudine Entecavir 

Notes

Acknowledgement

The authors who have taken part in this study declared that they do not have anything to disclose regarding grant support or conflict of interest with respect to this manuscript.

References

  1. 1.
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97–107PubMedCrossRefGoogle Scholar
  2. 2.
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–242CrossRefGoogle Scholar
  3. 3.
    Niu C, Murakami E, Furman PA. Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Antivir Ther 2008;13:263–269PubMedGoogle Scholar
  4. 4.
    Asselah T, Lada O, Moucari R, Marcellin P. Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2008;17:1963–1974PubMedCrossRefGoogle Scholar
  5. 5.
    Balakrishna Pai S, Liu SH, Zhu YL, Chu CK, Cheng YC. Inhibition of hepatitis B virus by a novel l-nucleoside, 2′-fluoro-5-methyl-beta-l-arabinofuranosyl uracil. Antimicrob Agents Chemother 1996;40:380–386PubMedGoogle Scholar
  6. 6.
    Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172–1178PubMedCrossRefGoogle Scholar
  7. 7.
    Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041–1048PubMedCrossRefGoogle Scholar
  8. 8.
    Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 2004;101:638–640PubMedCrossRefGoogle Scholar
  9. 9.
    Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001;75:311–322PubMedCrossRefGoogle Scholar
  10. 10.
    Kim IH, Lee S, Kim SH, Kim SW, Lee SO, Lee ST, et al. Treatment outcomes of clevudine versus lamivudine at week 48 in naïve patients with HBeAg positive chronic hepatitis B. J Korean Med Sci 2010;25:738–745PubMedCrossRefGoogle Scholar
  11. 11.
    Kim MH, Kim KA, Lee JS, Lee HW, Kim HJ, Yun SG, et al. Efficacy of 48-week clevudine therapy for chronic hepatitis B. Korean J Hepatol 2009;15:331–337PubMedCrossRefGoogle Scholar
  12. 12.
    Ko SY, Kwon SY, Choe WH, Kim BK, Kim KH, Lee CH. Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study. Antivir Ther 2009;14:585–590PubMedGoogle Scholar
  13. 13.
    Kim HJ, Park DI, Park JH, Cho YK, Sohn CI, Jeon WK, et al. Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B. Liver Int 2010;30:834–840PubMedCrossRefGoogle Scholar
  14. 14.
    Dienstag J. Hepatitis B virus infection. N Engl J Med 2008;359:1486–1500PubMedCrossRefGoogle Scholar
  15. 15.
    Lee HJ, Eun JR, Lee CH, Hwang JS, Suh JI, Kim BS, et al. Long-term clevudine therapy in nucleos(t)ide-naive and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases. Korean J Hepatol 2009;15:179–192PubMedCrossRefGoogle Scholar
  16. 16.
    Lee JS, Park ET, Kang SS, Gu ES, Kim JS, Jang DS, et al. Clevudine demonstrates potent antiviral activity in naive chronic hepatitis B patients. Intervirology 2010;53:83–86PubMedCrossRefGoogle Scholar
  17. 17.
    Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol 2010;84:4494–4503PubMedCrossRefGoogle Scholar
  18. 18.
    Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283–290PubMedCrossRefGoogle Scholar
  19. 19.
    Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785–791PubMedCrossRefGoogle Scholar
  20. 20.
    Zoulim F, Poynard T, Degos F, Slama A, El Hasnaoui A, Blin P, et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006;13:278–288PubMedCrossRefGoogle Scholar
  21. 21.
    Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol 2009;51:829–834PubMedCrossRefGoogle Scholar
  22. 22.
    Seok JI, Lee DK, Lee CH, Park MS, Kim SY, Kim HS, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009;49:2080–2086PubMedCrossRefGoogle Scholar
  23. 23.
    Tak WY, Park SY, Jung MK, Jeon SW, Cho CM, Kweon YO, et al. Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients. Hepatol Res 2009;39:944–947PubMedCrossRefGoogle Scholar
  24. 24.
    Tak WY, Park SY, Cho CM, Jung MK, Jeon SW, Kweon YO, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol 2010;53:261–266PubMedCrossRefGoogle Scholar
  25. 25.
    Kim JH, Yim HJ, Jung ES, Jung YK, Kim JH, Seo YS, et al. Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48. J Viral Hepat 2010. doi: 10.1111/j.1365-2893.2010.01304.x
  26. 26.
    Jang JH, Kim JW, Jeong SH, Myung HJ, Kim HS, Park YS, et al. Clevudine for chronic hepatitis B: Antiviral response, predictors of response, and development of myopathy. J Viral Hepat 2010. doi: 10.1111/j.1365-2893.2010.01281.x
  27. 27.
    Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009;51:787–791PubMedCrossRefGoogle Scholar
  28. 28.
    Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486–495PubMedCrossRefGoogle Scholar
  29. 29.
    Yeon JE. Technique for the early detection of drug-resistant HBV DNA during antiviral therapy. Intervirology 2008;51(1):7–10PubMedCrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2010

Authors and Affiliations

  • Su Rin Shin
    • 1
  • Byung Chul Yoo
    • 2
  • Moon Seok Choi
    • 2
  • Dong Ho Lee
    • 3
  • Soon Mi Song
    • 3
  • Joon Hyoek Lee
    • 2
  • Kwang Cheol Koh
    • 2
  • Seung Woon Paik
    • 2
  1. 1.Department of Medicine, Kangnam Sacred Heart HospitalHallym UniversitySeoulKorea
  2. 2.Department of Medicine, Samsung Medical CentreSungkyunkwan University School of MedicineSeoulKorea
  3. 3.Digestive Disease Research CentreSamsung Medical CentreSeoulKorea

Personalised recommendations